Abstract
The subject matter described here relates to anti-PD-1 monoclonal antibodies with increased size that are capable of modulating T-cell activity. In certain embodiments the monoclonal antibody comprises an additional Fc domain or CD22 domain.
Full Text
What is claimed is:
The subject matter described here relates to anti-PD-1 monoclonal antibodies with increased size that are capable of modulating T-cell activity. In certain embodiments the monoclonal antibody comprises an additional Fc domain or CD22 domain.
Timeline
Filed
04/06/2026Published
07/30/2026Granted
Not AvailableIPC Codes(7)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
A61K 39/00:Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53)
A61P 35/00:Antineoplastic agents